AVEO - AVEO Pharmaceuticals, Inc.
1.99 0.00 (0.00%)
After hours: 5:53PM EST
| Previous Close | 2.0600 |
| Open | 2.0800 |
| Bid | 1.98 x 1000 |
| Ask | 1.99 x 27000 |
| Day's Range | 1.9700 - 2.1000 |
| 52 Week Range | 1.4900 - 3.5900 |
| Volume | 1,229,250 |
| Avg. Volume | 2,879,814 |
| Market Cap | 319.658M |
| Beta (3Y Monthly) | 2.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.20 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- Business Wire•2 days ago
AVEO Oncology Announces Immuno-Oncology Clinical Collaboration with AstraZeneca
AVEO Oncology (AVEO) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's IMFINZI® (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with FOTIVDA® (tivozanib), AVEO’s oral, once-daily, potent and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) in first-line hepatocellular carcinoma (HCC), or liver cancer, in a Phase 1/2 study. AVEO will serve as the study sponsor, with study costs shared equally by both parties and clinical drug supplied by each respective company. “We are thrilled to collaborate with AstraZeneca to explore another tivozanib-immunotherapy combination and look forward to understanding the potential of combining tivozanib with durvalumab in liver cancer,” said Michael Bailey, president and chief executive officer of AVEO.
- Motley Fool•3 days ago
Why AVEO Pharmaceuticals Stock Tanked Last Month
The company's meager cash position is worrying investors.
- Business Wire•9 days ago
AVEO Oncology Announces Extension of Debt Facility Interest Only Period
AVEO Oncology (AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with Hercules Capital, Inc. (Hercules). The extension was granted as a result of achieving certain predefined requirements under the agreement, including successfully meeting the primary endpoint of the Company’s Phase 3 TIVO-3 study of tivozanib in refractory advanced or metastatic renal cell carcinoma (RCC), by demonstrating a significant improvement in progression free survival. The Company will begin making principal payments on the $20.0 million facility starting on August 1, 2019.
- TheStreet.com•15 days ago
2 Small Biotech Stocks That Insiders Are Buying
The biotech sector continues to see bearish sentiment and trading action. Small biotech stocks rallied just over 2% on Monday to begin a new trading week, but all those gains were given right back in Tuesday's session.
- GlobeNewswire•15 days ago
New Research Coverage Highlights AVEO Pharmaceuticals, GMS, R1 RCM, Installed Building Products, Stoneridge, and Chicago Rivet & Machine — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- American City Business Journals•22 days ago
Former Aveo CFO misled biotech's investors, jury finds
The SEC accused David Johnston of failing to disclose that the FDA had recommended that Aveo conduct a second late-stage trial of a kidney cancer drug, which was ultimately rejected.
- Zacks•23 days ago
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
- ACCESSWIRE•23 days ago
4 Healthcare Stocks You Should Get To Know Before 2019
New market trends are pushing investors to pay closer attention to the healthcare industry as it has been seen as a safe haven during turbulent times in the broader markets. In fact, according to the "Cognitive Computing and Artificial Intelligence Systems Market in Healthcare" report from ResearchAndMarkets these technologies have gained significant traction. Increased adoption of cognitive and AI platforms can be attributed to their wide application potential across the healthcare industry, including patients and hospitals.
- Business Wire•24 days ago
AVEO Oncology to Present at the 30th Annual Piper Jaffray Healthcare Conference
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com.
- Business Wire•29 days ago
AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA®
AVEO Oncology (AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC.
- ACCESSWIRE•29 days ago
Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity
HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...
- Zacks•last month
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.
- Zacks•last month
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 262.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
AVEO: 3Q Earnings Snapshot
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 18 cents. Losses, adjusted for non-recurring costs, were 5 cents per share. The results beat Wall Street expectations. ...
- Business Wire•last month
AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update
AVEO Oncology today reported financial results for the third quarter ended September 30, 2018 and provided a business update.
- Business Wire•last month
AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint
AVEO Oncology (AVEO) today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC). The trial met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS). Among these, approximately 26% of patients received checkpoint inhibitor therapy in earlier lines of treatment.
- Zacks•last month
Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire•2 months ago
AVEO Oncology and EUSA Pharma Announce Updated Interim Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma
AVEO Oncology (AVEO) and EUSA Pharma today announced the presentation of updated interim results from the Phase 2 portion of the TiNivo study, a Phase 1b/2 multicenter trial of oral (PO) tivozanib (FOTIVDA®) in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma. The results were presented today at European Society of Medical Oncology (ESMO) 2018 Annual Congress, in a poster presentation titled “TiNivo: Tivozanib Combined with Nivolumab: Safety and Efficacy in Patients with Metastatic Renal Cell Carcinoma (mRCC)” (Presentation 878P).
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Aethlon Medical, Jaguar Animal Health, Advaxis, Forestar Group, Platform Specialty Products, and AVEO Pharmaceuticals — Discovering Underlying Factors of Influence
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Motley Fool•2 months ago
Why AVEO Pharmaceuticals, Inc. Stock Perked Up in September
AVEO is close to a key clinical readout that could prove to be a major catalyst for its stock.
- Zacks•2 months ago
Do Options Traders Know Something About AVEO Stock We Don't?
Investors need to pay close attention to AVEO stock based on the movements in the options market lately.
- Business Wire•2 months ago
AVEO Oncology to Present Updated Interim Results from the Phase 2 Portion of the TiNivo Study of Tivozanib and Nivolumab (OPDIVO®) in RCC at the ESMO 2018 Annual Congress
AVEO Oncology (AVEO) today announced that updated interim data from the Phase 2 portion of the TiNivo trial of tivozanib and nivolumab (OPDIVO®) in advanced renal cell carcinoma will be presented at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. The TiNivo study is a Phase 1b/2 multicenter trial of oral tivozanib (FOTIVDA®) in combination with intravenous nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of metastatic renal cell carcinoma (mRCC). The accepted abstract, which includes results from a poster presentation at the 2018 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January, is available via the ESMO 2018 Annual Congress website.
- Business Wire•2 months ago
AVEO Oncology Announces Initiation of Topline Analysis of Phase 3 TIVO-3 Trial
AVEO Oncology (AVEO) today announced that it has initiated topline analysis of the phase 3 TIVO-3 clinical trial on the unanimous recommendation of the independent TIVO-3 Study Steering Committee, and after notice to the FDA. The TIVO-3 trial is the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® (tivozanib) to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). The Company expects to complete data analysis and report topline results from the study in approximately 6 weeks.
- Zacks•3 months ago
AVEO Pharmaceuticals (AVEO) Soars: Stock Adds 6.4% in Session
AVEO Pharmaceuticals (AVEO) shares rose more than 6% in the last trading session, amid huge volumes.
- ACCESSWIRE•3 months ago
Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Heron Therapeutics
NEW YORK, NY / ACCESSWIRE / September 26, 2018 / U.S. equities were mixed on Tuesday as concerns of a potential trade war linger and investors look forward to details from the upcoming Fed monetary policy ...
